| Literature DB >> 30071584 |
Angélica Graça1, Lídia Maria Gonçalves2, Sara Raposo3,4, Helena Margarida Ribeiro5, Joana Marto6,7.
Abstract
Polymer-based eye drops are the most used drug delivery system to treat dry eye disease (DED). Therefore, the mucoadhesion between the polymer and the ocular mucin is crucial to ensure the efficacy of the treatment. In this context, the present study aimed to evaluate the potential use of in vitro methods to study the mucoadhesion of eye drop solutions and, specifically to evaluate the efficacy of two hyaluronic acid-based formulations (HA), HA 0.15% and 0.30% (w/v) to treat DED. Rheology methods and zeta potential determination were used to study the mucoadhesive properties of both eye drop solutions. All results indicated that interactions occurred between the mucin and the HA, being stronger with HA 0.30%, due to the physical entanglements and hydrogen bounding. In vitro tests on ARPE-19 cell line were performed using a 2D and a 3D dry eye model and the results have shown that pre-treated cells with HA showed a morphology more similar to the hydrated cells in both products, with a high survival rate. The in vitro techniques used in this study have been shown to be suitable to evaluate and predict mucoadhesive properties and the efficacy of the eye drops on relief or treatment of DED. The results obtained from these methods may help in inferring possible in vivo effects.Entities:
Keywords: dry eye disease; eye drops; hyaluronic acid; in vitro tests; medical devices; mucoadhesion
Year: 2018 PMID: 30071584 PMCID: PMC6161121 DOI: 10.3390/pharmaceutics10030110
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Physical-chemical aspects of HA 0.15% and HA 0.30% (w/v) eye drop solutions.
| Tests | Specifications | HA 0.15% Eye Drop Solutions | HA 0.3% Eye Drop Solutions |
|---|---|---|---|
|
| Limpid, clear and odorless solution | Limpid, clear and odorless solution | Limpid, clear and odorless solution |
|
| 7.0–7.6 at 20–25 °C | 7.16 (23.2 °C) | 7.32 (20.8 °C) |
|
| 280–320 mOsm/Kg | 302 mOsm/Kg | 304 mOsm/Kg |
|
| Absence of growth | Absence of growth | Absence of growth |
Viscosity values and mucoadhesive index for HA 0.15% (w/v) and HA 0.30% (w/v) in absence and presence of mucin 5% (w/w) (mean ± SD, n = 3).
| Formulations | Viscosity (mPa·s) | Mucoadhesive Index (%) |
|---|---|---|
|
| 6.8 ± 0.1 | - |
|
| 71.2 ± 4.1 | - |
|
| 25.0 ± 0.6 | - |
|
| 53.2 ± 1.1 * | 298.07 ± 19.90 * |
|
| 382.2 ± 0.4 * | 67.44 ± 6.24 * |
* Significant statistical differences between both formulations (p < 0.05).
Figure 1Frequency sweep with shear moduli as function of frequency of HA 0.15%, Mucin 5% and Mucin + HA 0.15% (A) and of HA 0.30%, Mucin 5% and Mucin + HA 0.30% (B) at room temperature.
Normal force and area under force-time curve results for HA 0.15%, HA 0.30%, CR 0.15%, CR 0.30%, Mucin, Mucin + HA 0.15% and Mucin + HA 0.30% (Mean ± SD, n = 6).
| Formulations | Peak Normal Force-Normal Force (N) | Area Under Force-Time Curve (N·s) |
|---|---|---|
|
| −0.178 ± 0.003 * | 0.438 ± 0.058 * |
|
| −0.229 ± 0.013 * | 0.775 ± 0.091 * |
|
| −0.168 ± 0.017 | 0.904 ± 0.069 |
|
| −0.220 ± 0.007 | 1.051 ± 0.043 |
|
| −0.228 ± 0.004 * | 1.012 ± 0.065 * |
|
| −0.216 ± 0.019 * | 0.573 ± 0.152 * |
|
| −0.287 ± 0.030 * | 0.747 ± 0.066 * |
|
| −0.078 ± 0.029 * | 0.891 ± 0.060 * |
|
| −0.134 ± 0.034 * | 1.010 ± 0.059 * |
*1 Mean ± SD, n = 6; *2 Mean ± SD, three different eyes, n = 3; * Significant statistical differences between both formulations p < 0.05.
Figure 2Determination of zeta potential for HA 0.15%, HA 0.30%, Mucin 5% and both products with mucin, values in absolute (Mean ± SD, n = 3).
Figure 3Results of cell viability on ARPE-19 cell lines testing CR 0.30%, CR 0.15%, HA 0.30% and HA 0.15% at various concentrations (mean ± SD, n = 8).
Optical microscope images of ARPE-19 after dehydration in no protective conditions (dry eye), after dehydration preceded by treatment with HA formulations and cells not submitted to dehydration (medium).
| Without Die Magnification 100× | Crystal Violet Magnification 200× | Crystal Violet Magnification 400× | Cell Viability (%) | |
|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Figure 4Cell viability of ARPE-19 cell lines exposed for 24 h to HA 0.15% and HA 0.30% formulations and commercial formulation (CR) containing 0.30% of hyaluronic acid (mean ± SD, n = 9). (* Significant statistical differences between both formulations p < 0.05).